Martin K. Bayliss - Concepedia

Author

Martin K. Bayliss

Also Known As

M Bayliss, M K Bayliss, M. K. BAYLISS, M. K. Bayliss, M.K Bayliss, M.K. BAYLISS, M.K. Bayliss, MARTIN K. BAYLISS, Martin Bayliss, Martin K Bayliss

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

University of Hertfordshire GlaxoSmithKline (United Kingdom)Wellcome Library University of Manchester Research Triangle Park Foundation

About

Martin K. Bayliss is an author at University of Hertfordshire specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	17	658
2	Biochemistry	11	11	551
3	Natural Sciences	4	4	123
4	Health Sciences	3	3	129
5	Education	1	1	10

Martin K. Bayliss

Publications

966

Citations

H-Index

Page 1

	Year	Citations
ADME/PK as part of a rational approach to drug discovery Peter Eddershaw, Alan Beresford, Martin K. Bayliss Drug Discovery Today Drug TargetBiochemistryMedicineRational Drug DesignPharmacology	2000	237
Microsomal prediction of <i>in vivo</i> clearance of CYP2C9 substrates in humans David Carlile, Nancy Hakooz, Martin K. Bayliss, British Journal of Clinical Pharmacology	1999	117
Parallel ultra-high flow rate liquid chromatography with mass spectrometric detection using a multiplex electrospray source for direct, sensitive determination of pharmaceuticals in plasma at extremely high throughput Martin K. Bayliss, David Little, David N. Mallett, Rapid Communications in Mass Spectrometry	2000	83
A Comparison of the Expression and Metabolizing Activities of Phase I and II Enzymes in Freshly Isolated Human Lung Parenchymal Cells and Cryopreserved Human Hepatocytes Graham Somers, N. Lindsay, B. M. Lowdon, Drug Metabolism and Disposition	2007	78
Utility of hepatocytes to model species differences in the metabolism of loxtidine and to predict pharmacokinetic parameters in rat, dog and man Martin K. Bayliss Xenobiotica Species DifferencesIntrinsic ClearanceExperimental PharmacologyPharmacological StudyToxicology	1999	70
The use of Long-term Hepatocyte Cultures for Detecting Induction of Drug Metabolising Enzymes: The Current Status Sandra Coecke, Vera Rogiers, Martin K. Bayliss, Alternatives to Laboratory Animals Drug Metabolising EnzymesMetabolomic ProfilingPathologyMetabolic ModelPrevalidation Proposal	1999	48
Prediction of intrinsic clearance of loxtidine from kinetic studies in rat, dog and human hepatocytes Martin K. Bayliss, John Bell, WILLIAM N. JENNER, Biochemical Society Transactions Intrinsic ClearanceExperimental PharmacologyLaboratory Animal StudyIntegrative PhysiologySystems Pharmacology	1990	36
The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A. Gary R. Manchee, Peter Eddershaw, Lisa E. Ranshaw, PubMed Salmeterol XinafoateLipid PeroxidationPharmacotherapyChemical BiologyExperimental Pharmacology	1996	30
7-Ethoxycoumarin<i>O</i>-deethylase kinetics in isolated rat, dog and human hepatocyte suspensions Martin K. Bayliss, J. A. Bell, K. Wilson, Xenobiotica	1994	30
Pharmacokinetic Optimization in Drug Research Tony Pateman, Martin K. Bayliss Drug Discovery Today PharmacodynamicsPharmacologyDrug ResearchMedicinePharmacokinetics	2001	29

Page 1